Page 82 - GPD-2-3

Gene & Protein in Disease

CASE REPORT
Clinical debate on papillary thyroid

microcarcinoma-could genetic testing change
the decision of papillarythyroid microcarcinoma

(mPTC) treatment: A case report

1
1
3
Haitao Peng 1,2† , Chang cai , Zifeng Luo , Chong Wang , Yuanwei Luo , and
1†
1
Song Wang *
1 Department of Thyroid and Breast Surgery, Key Laboratory of Biological Targeting Diagnosis
Therapy and Rehabilitation of Guangdong Higher Education Institutes, The Fifth Affiliated Hospital
of Guangzhou Medical University, Guangzhou, Guangdong, China
2 Department of Thyroid and Breast Surgery, Shantou Third Peoples Hospital, Shantou, Guangdong,
China
3 School of International Studies, Hunan Institute of Technology, Hengyang, Hunan, China

Abstract

The objective of this case report is to explore whether genetic testing is appropriate
to guide the treatment of papillary thyroid microcarcinoma (PTMC). In this case
report, we describe a 27-year-old female who had no significant medical history and
no tumor detected in the thyroid gland by ultrasound or computed tomography (CT),
† These authors contribute equally to
this work. but had multiple enlarged lymph nodes at the right cervical lymph node levels II, III,
IV, and V. The intraoperative frozen section pathology results showed that seven out
*Corresponding author: of 23 right lymph nodes were metastatic from thyroid papillary carcinoma, but no
Song Wang
(gzwangmomo1983@sina.com) primary lesion was found in the thyroid gland. After multiple post-operative sampling
and micro section, only a 1 mm papillary carcinoma in the left thyroid gland was
Citation: Peng H, Cai C, Luo Z,
et al., 2023, Clinical debate on identified. The genetic testing result showed that the patient was positive for CCDC6-
papillary thyroid microcarcinoma exon 1-RET-exon 12 fusion. The final diagnosis of the patient was left thyroid micro-
could genetic testing change papillary carcinoma (1 mm) with the right lateral cervical lymph node metastasis. She
the decision of papillary thyroid
microcarcinoma (mPTC) treatment: received iodine-131 treatment with nuclide and lifelong levothyroxine therapy in the
rd
A case report. Gene Protein Dis, 3 month after surgery. Continuous follow-up showed no elevation of thyroglobulin,
2(3): 0371. no recurrence signs on positron emission tomography-CT re-examination, and good
https://doi.org/10.36922/gpd.0371
self-reported health status. In conclusion, the identification of CCDC6-RET fusion by
Received: March 28, 2023 genetic testing in the PTMC case aided diagnosis and treatment.
Accepted: August 9, 2023
Published Online: August 30, 2023
Copyright: © 2023 Author(s). Keywords: Papillary thyroid microcarcinoma; Thyroid cancer; Active surveillance; CCDC6-
This is an Open-Access article RET fusion; Genetic testing
distributed under the terms of the
Creative Commons Attribution
License, permitting distribution, and
reproduction in any medium, which
provided that the original work is 1. Introduction
properly cited.
Papillary thyroid carcinoma (PTC), which accounts for more than half of the thyroid
Publisher’s Note: AccScience
[1]
Publishing remains neutral with microcarcinoma (PTMC) cases, has a diameter of ≤1 cm . Considering the inert nature
regard to jurisdictional claims in of all PTMCs, PTMC is usually slow-growing, with uncomplicated clinical presentation,
published maps and institutional
affiliations. and rarely endangers the patient’s life. In recent years, PTMC metastasis to lymph

Volume 2 Issue 3 (2023) 1 https://doi.org/10.36922/gpd.0371